Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01541306 · ClinicalTrials.gov registry record
C-Type Natriuretic Peptide and Achondroplasia
A clinical trial of Achondroplasia and Hypochondroplasia, sponsored by Nemours Children's Clinic.
- Completed
- Registry status
- 91
- Enrollment target
- 1
- Study location
NCT01541306: Completed study of Achondroplasia and Hypochondroplasia, sponsored by Nemours Children's Clinic.
NCT01541306 is a study of Achondroplasia and Hypochondroplasia that has completed, run by Nemours Children's Clinic. The registered enrollment target is 91 participants, below the 141-participant average among 9 other Achondroplasia trials with a reported enrollment target (35% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01541306, a study of Achondroplasia and Hypochondroplasia, has completed, sponsored by Nemours Children's Clinic.
- COMPLETED
- Registry status
- 91 participants
- Enrollment target
- 1
- Study location
Study Summary
Achondroplasia and hypochondroplasia are the most common forms of dwarfism. Recent studies have shown that a small hormone called C-type natriuretic peptide (CNP) is an important regulator of linear growth. The investigators believe that genetic abnormality that causes achondroplasia and hypochondroplasia also disrupts CNP signaling, which may contribute to the growth problem. The investigators propose to look at levels of this and other closely related hormones in children and adults with achondroplasia or hypochondroplasia to see if they are different from levels in healthy people. The investigators hypothesis is that CNP levels are elevated in children with achondroplasia or hypochondroplasia, compared the healthy population. Another hypothesis is that CNP levels are not elevated in adults with achondroplasia or hypochondroplasia, since adults have no growth-plate cartilage. By studying the potential role of the CNP system in achondroplasia and hypochondroplasia, not only will the investigators provide further insight into the pathophysiology of these common syndromes, the investigators will also provide greater insight into the regulation of normal linear growth.
Primary Outcome
Aminoterminal propeptide of CNP (NTproCNP) is measured in plasma by RIA and compared to an existing sex- and age- based reference range.
Conditions Studied
Study Locations (1)
Delaware
- Alfred I. duPont Hospital for Children - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2012-02 |
| Est. Completion | 2014-12 |
What the finished NCT01541306 record still lists
NCT01541306 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 91 participants, a relatively small participant target, below the 141-participant average among 9 other Achondroplasia trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Achondroplasia appearing as the primary indexed condition, and to 0 interventions.
NCT01541306 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT01541306 about?
NCT01541306 is a clinical study titled "C-Type Natriuretic Peptide and Achondroplasia". Achondroplasia and hypochondroplasia are the most common forms of dwarfism. Recent studies have shown that a small hormone called C-type natriuretic peptide (CNP) is an important regulator of linear growth. The investigators believe that genetic abnormality that causes achondroplasia and hypochondro...
What is the current status of trial NCT01541306?
This trial is currently completed. The enrollment target is 91 participants. The study started on 2012-02. Estimated completion is 2014-12.
What conditions does trial NCT01541306 study?
This clinical trial studies the following conditions: Achondroplasia, Hypochondroplasia.
Who is sponsoring clinical trial NCT01541306?
This trial is sponsored by Nemours Children's Clinic, which has 108 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01541306 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Achondroplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01541306's enrollment target sits among peer trials
91 6th of 9 higher than 4 of 9 other Achondroplasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Achondroplasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Interventional Study of Infigratinib in Children < 3 Years Old With Achondroplasia (ACH)
RECRUITING · Phase 2
-
A Study of TYRA-300 in Children With Achondroplasia: BEACH301
RECRUITING · Phase 2
-
VIrtual STudy in Achondroplasia for the US (VISTA)
RECRUITING
-
A Clinical Trial to Evaluate Efficacy and Safety of TransCon CNP Compared With Placebo in Infants (0 to <2 Years of Age) With Achondroplasia
RECRUITING · Phase 2
-
An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate Long-Term Safety, Tolerability, & Efficacy of BMN 111 in Children With Achondroplasia (ACH)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02671448 · 91 participants · NA
Pilot Trial of Homebound Stem Cell Transplantation
- NCT04835857 · 91 participants
Comparison of Cuff-Less Wrist Wearable Blood Pressure Device to Cuff Based Blood Pressure Measuring Devices
- NCT05184842 · 91 participants · Phase 2
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
- NCT05685173 · 91 participants · Phase 1
A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia